Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials-Reference-Cited by-同舟云学术

Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials

Published:2020-01-24 Issue:1 Volume:15 Page:e0227344
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Faury Stéphane,Foucaud Jérôme^ORCID

Funder

Institut National Du Cancer

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference84 articles.

1. Role of pembrolizumab in the treatment of non-small cell lung cancer (NSCLC);G Gálffy;Magy Onkol,2017

2. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape;LA Emens;Eur J Cancer,2017

3. Immunotherapy and novel combinations in Oncology: current Landscape; challenges and opportunities;KM Morrissey;Clin Transl Sci,2016

4. Immune Checkpoint Inhibitors: An innovation on Immunotherapy for the Treatment and Management of Patients with Cancer;J Dine;Asia Pac J Oncol Nurs,2017

5. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;SL Topalian;N Engl J Med,2012

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Comparison of Health-Related Quality of Life Associated with Use of Immune-Checkpoint Inhibitors in Oncology Patients;Journal of Clinical Medicine;2024-08-20

2. Assessing patient-reported outcomes (PROs) and patient-related outcomes in randomized cancer clinical trials for older adults: Results of DATECAN-ELDERLY initiative;Journal of Geriatric Oncology;2024-01

3. COVID-19;Manson's Tropical Diseases;2024

4. Linkage between Psychological Factors and Response to Immune Checkpoint Inhibitor Therapy: A Preliminary Study;Cells;2023-10-17

5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer;Journal for ImmunoTherapy of Cancer;2023-06